Travere Therapeutics Inc (NASDAQ: TVTX) is 97.78% higher on its value in year-to-date trading and has touched a low of $5.12 and a high of $20.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TVTX stock was last observed hovering at around $17.13 in the last trading session, with the day’s gains setting it 0.65%.
Currently trading at $17.78, the stock is -2.32% and -1.93% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.81 million and changing 3.79% at the moment leaves the stock 57.12% off its SMA200. TVTX registered 88.55% gain for a year compared to 6-month gain of 114.73%. The firm has a 50-day simple moving average (SMA 50) of $18.1283 and a 200-day simple moving average (SMA200) of $11.266125.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.20% loss in the last 1 month and extending the period to 3 months gives it a 18.22%, and is 5.46% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.21% over the week and 4.17% over the month.
Travere Therapeutics Inc (TVTX) has around 380 employees, a market worth around $1.55B and $203.45M in sales. Profit margin for the company is -172.78%. Distance from 52-week low is 247.27% and -12.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-117.93%).
with sales reaching $70.89M over the same period.The EPS is expected to shrink by -161.54% this year, but quarterly earnings will post 58.60% year-over-year. Quarterly sales are estimated to grow 57.33% in year-over-year returns.
The shares outstanding are 87.03M, and float is at 85.74M with Short Float at 8.64%.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.64 million shares valued at $62.84 million. The investor’s holdings represent 9.8642 of the TVTX Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 7.5 million shares valued at $61.65 million to account for 9.6774 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 7.37 million shares representing 9.5096 and valued at over $60.58 million, while VANGUARD GROUP INC holds 8.5416 of the shares totaling 6.62 million with a market value of $54.41 million.
Travere Therapeutics Inc (TVTX) Insider Activity
Travere Therapeutics Inc disclosed in a document filed with the SEC on Nov 25 ’24 that Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) sold a total of 12,090 shares of the company’s common stock. The trade occurred on Nov 25 ’24 and was made at $18.30 per share for $0.22 million. Following the transaction, the insider now directly holds 54927.0 shares of the TVTX stock.
Still, SEC filings show that on Nov 25 ’24, Calvin Sandra (Officer) Proposed Sale 12,090 shares at an average price of $18.30 for $0.22 million. The insider now directly holds shares of Travere Therapeutics Inc (TVTX).
